Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

NCT02826603 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1114

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Secukinumab
DRUG: Ustekinumab

Sponsor

Novartis Pharmaceuticals